Evidence map›Paper›PMID 36133203›Full record

ArticleNanoscale advances2019

Advanced microscopic evaluation of parallel type I and type II cell deaths induced by multi-functionalized gold nanocages in breast cancer.

Sreejith Raveendran, Anindito Sen, Hiromi Ito-Tanaka, Kazunori Kato, Toru Maekawa, D Sakthi Kumar

Abstract read
In one paragraph

Article in Nanoscale advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sreejith RaveendranBio-Nano Electronics Research Centre, Graduate School of Interdisciplinary New Science, Toyo University 2100, Kujirai, Kawagoe Saitama 350-8585 Japan sakthi@toyo.jp +81 49 234 2502 +81 49 239 1375.ORCID https://orcid.org/0000-0001-7499-304X
Anindito SenJEOL Ltd. 13F, Ohtemachi Nomura Building, 2-1-1 Ohtemachi Chiyoda-Ku Tokyo Japan.
Hiromi Ito-TanakaDepartment of Biomedical Engineering, Research Centre for BME, Toyo University 2100, Kujirai, Kawagoe Saitama 350-8585 Japan.
Kazunori KatoDepartment of Biomedical Engineering, Research Centre for BME, Toyo University 2100, Kujirai, Kawagoe Saitama 350-8585 Japan.
Toru MaekawaBio-Nano Electronics Research Centre, Graduate School of Interdisciplinary New Science, Toyo University 2100, Kujirai, Kawagoe Saitama 350-8585 Japan sakthi@toyo.jp +81 49 234 2502 +81 49 239 1375.
D Sakthi KumarBio-Nano Electronics Research Centre, Graduate School of Interdisciplinary New Science, Toyo University 2100, Kujirai, Kawagoe Saitama 350-8585 Japan sakthi@toyo.jp +81 49 234 2502 +81 49 239 1375.ORCID https://orcid.org/0000-0003-4819-2032

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite aggressive surgical resections and combinatorial chemoradiations, certain highly malignant populations of tumor cells resurrect and metastasize. Mixed-grade cancer cells fail to respond to standard-of-care therapies by developing intrinsic chemoresistance and subsequently result in tumor relapse. Macroautophagy is a membrane trafficking process that underlies drug resistance and tumorigenesis in most breast cancers. Manipulating cellular homeostasis by a combinatorial nanotherapeutic model, one can evaluate the crosstalk between type I and type II cell death and decipher the fate of cancer therapy. Here, we present a multi-strategic approach in cancer targeting to mitigate the autophagic flux with subcellular toxicity

Identifiers

PMID36133203
PMCPMC9473243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.